Insurance Prior Authorization Checklist for GLP-1s (Printable Patient Guide)

Navigating insurance requirements for GLP-1 medications like Wegovy, Ozempic, or Zepbound can be a frustrating experience. With prior authorizations now mandatory for most plans, a successful approval depends entirely on a complete and well-documented submission.

This guide provides a comprehensive, step-by-step checklist to help you and your doctor gather the necessary paperwork, understand the insurer's criteria, and effectively appeal a denial. We'll walk through the entire process, from initial submission to the latest 2026 Medicare coverage changes, to empower you on your treatment journey.

By | Medically Reviewed by Dr. John Doe, PharmD | Last Updated:

Key Takeaways

  • PA is Mandatory: Over 88% of insurance plans that cover GLP-1 medications for weight loss now require prior authorization (PA) [1].
  • Documentation is Crucial: Success depends on providing detailed medical records, including BMI, weight-related health conditions, and proof of prior lifestyle modification attempts.
  • Denials Are Common, Appeals Work: Initial rejection rates are high (over 60%), but many denials are overturned on appeal with proper documentation and a letter of medical necessity [2].
  • Know Your Plan's Rules: Insurers have specific criteria, such as BMI thresholds (often 30+, or 27+ with comorbidities) and step therapy (trying other medications first).
  • Medicare is Changing: Starting in 2026, new CMS models will expand Medicare coverage for GLP-1s for obesity, but prior authorization will still be a key step [3].

Quick Answer: How Do I Get Prior Authorization for Wegovy, Ozempic, or Zepbound?

To get prior authorization for a GLP-1 medication, your doctor must submit a formal request to your insurance company proving the drug is medically necessary for you. This involves providing detailed documentation of your diagnosis (e.g., obesity, type 2 diabetes), your Body Mass Index (BMI), a history of related health conditions like hypertension or sleep apnea, and evidence that you have tried other methods like diet and exercise. The insurer reviews this packet against their specific coverage rules. If approved, you can get the medication; if denied, you have the right to appeal the decision, a process that is often successful when more detailed clinical information is provided.

Medical Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment. The information on prior authorization is based on data available as of February 2026 and is subject to change. Synedica is not affiliated with any insurance provider or pharmaceutical manufacturer mentioned.

What is Prior Authorization and Why Do GLP-1s Require It?

Prior authorization (PA), also known as pre-authorization or pre-certification, is a cost-control process used by health insurance companies in the United States to determine if they will cover a prescribed procedure, service, or medication. Before you can receive your medication, your insurer requires your healthcare provider to justify its medical necessity. This process has become nearly universal for high-cost, popular medications like the GLP-1 receptor agonists.

GLP-1s such as Wegovy, Ozempic, Mounjaro, and Zepbound are a primary target for prior authorization for two main reasons:

  1. High Cost: These drugs have a list price of over $1,000 per month, creating a significant financial liability for insurers.
  2. High Demand: Skyrocketing popularity for both type 2 diabetes and weight management has led to a surge in prescriptions, prompting insurers to implement stricter controls to manage spending.

Recent data highlights this trend dramatically. According to a study published in JAMA Network Open, prior authorization requirements for these therapies in Medicare Part D plans surged from under 25% in mid-2023 to over 83% by 2024 [4]. For many commercial plans, the rate is even higher, with some analyses showing that nearly 9 in 10 patients with coverage will face a PA requirement [1].

The Step-by-Step Prior Authorization Process: A Patient's Guide

Navigating the prior authorization process can feel daunting, but understanding the steps can empower you to work more effectively with your doctor and insurance company. The process generally follows a standard path from submission to decision.

Step Action Key Details & Timeline
1 Prescription & PA Trigger Your doctor prescribes a GLP-1 medication. The pharmacy receives the prescription and, upon seeing the insurance requirement, notifies your doctor that a PA is needed.
2 Information Gathering Your doctor's office compiles the necessary clinical documentation. This is the most critical and time-consuming step. (See checklist below for required documents).
3 Submission Your provider submits the PA request to your insurer, typically through an electronic portal like CoverMyMeds or by faxing a standardized form.
4 Insurer Review A clinical pharmacist or medical director at the insurance company reviews your case against their internal coverage policies.
5 Decision The insurer issues a decision. Per new 2026 CMS rules, this must happen within 72 hours for urgent requests and 7 calendar days for standard requests [5].
6 Approval or Denial If approved, the pharmacy is notified and you can fill your prescription. If denied, you will receive a formal denial letter explaining the reason.
7 Appeal (If Denied) You and your doctor have the right to appeal the denial, which starts a new review process.

The Ultimate Prior Authorization Checklist

Success in securing a prior authorization hinges on a complete and well-documented submission. Use this checklist to gather everything you and your doctor will need. A printable version is available for download to take to your next appointment.

Download the Printable PDF Checklist

Section 1: Patient & Diagnosis Information

  • Patient Information: Full Name, Date of Birth, Insurance ID & Group Number
  • Prescriber Information: Name, NPI Number, Clinic Contact Information
  • Medication Requested: Drug Name (e.g., Wegovy), Dosage, and Quantity
  • Primary Diagnosis Code (ICD-10):
    • E66.01 (Morbid/Severe Obesity)
    • E66.09 (Other Obesity)
    • E11.9 (Type 2 Diabetes Mellitus without complications)
  • Secondary Diagnoses (Comorbidities): List all relevant weight-related conditions.

Section 2: Clinical Evidence & Medical History

  • Current Body Mass Index (BMI): Must meet your plan's threshold (e.g., ?30 kg/m? or ?27 kg/m?).
  • Documented Comorbidities: Provide records for conditions such as:
    • Hypertension (High Blood Pressure)
    • Dyslipidemia (High Cholesterol)
    • Obstructive Sleep Apnea (OSA)
    • Cardiovascular Disease
    • Non-alcoholic Fatty Liver Disease (NAFLD)
  • History of Failed Weight Loss Attempts: Proof of participation in a structured diet and exercise program for at least 3-6 months.
  • Step Therapy Documentation (If Required): Evidence of trying and failing preferred, lower-cost alternatives (e.g., metformin, liraglutide/Saxenda).
  • Relevant Lab Work:
    • A1C (for diabetes diagnosis)
    • Fasting Lipid Panel (for dyslipidemia)
    • Liver Function Tests (LFTs)

Section 3: Supporting Documentation

  • Letter of Medical Necessity (LMN): A detailed letter written by your doctor explaining why this specific medication is essential for your health, outlining the risks of not treating your condition, and summarizing the supporting clinical evidence.
  • Recent Chart Notes: Clinical notes from recent visits detailing your condition, treatment plan, and progress.
  • Specialist Consultation Reports: If you have seen a specialist like an endocrinologist or cardiologist, include their reports.

What to Do If Your Prior Authorization is Denied

An initial denial is not the end of the road. In fact, it is a very common part of the process. Insurers often issue automated denials hoping patients will give up. However, persistence pays off.

  1. Analyze the Denial Letter: The letter is required to state the specific reason for the denial. It may be a simple administrative error (e.g., missing paperwork) or a clinical reason (e.g., "does not meet BMI criteria").
  2. Request a Peer-to-Peer Review: Your doctor can request a phone call with a medical director from the insurance company to discuss your case directly. This is often the fastest way to overturn a denial.
  3. File an Internal Appeal: You have the right to a formal internal appeal. For this, your doctor will resubmit the PA request with additional information, a stronger letter of medical necessity, and potentially citations from clinical studies to bolster your case. The deadline to file is typically 60-180 days.
  4. Initiate an External (Independent) Review: If the internal appeal is also denied, you can request an external review by an independent third party. These reviews have a high success rate, as they focus purely on medical evidence without the insurer's financial bias.

Medicare Coverage for GLP-1s: Big Changes in 2026

Historically, Medicare has been legally prohibited from covering medications for weight loss alone. However, significant changes are on the horizon.

Under the new CMS BALANCE (Better Approaches to Lifestyle and Nutrition to Create Equity) model, Medicare is set to expand access to GLP-1s for obesity. Starting in April 2026, the model will allow coverage for beneficiaries who have obesity and at least one qualifying comorbidity, such as heart disease [3, 6]. A separate payment demonstration will also launch in July 2026 to help make these drugs more affordable for Part D enrollees.

While this is a landmark shift, it does not eliminate the need for prior authorization. Beneficiaries will still need to meet specific clinical criteria to qualify for coverage.

Frequently Asked Questions

How long does a prior authorization approval last?

An initial approval is typically valid for 6 months. For renewals, your insurer will require documentation from your doctor showing a positive clinical response, such as achieving and maintaining at least a 5% weight loss from your starting weight.

What is "step therapy"?

Step therapy is a type of prior authorization where your insurer requires you to try one or more lower-cost "preferred" medications first. If those drugs are not effective or cause intolerable side effects, your doctor can then submit a PA request for the originally prescribed, more expensive medication.

Can I pay out-of-pocket if my PA is denied?

Yes, you can always choose to pay the full cash price for the medication. However, this can be very expensive. It is worth exploring manufacturer savings programs (like the NovoCare Wegovy Savings Card) and patient assistance programs, which can significantly lower the cost if you meet their eligibility criteria.

Why was my PA denied even though I have Type 2 Diabetes?

A denial for a patient with type 2 diabetes is often due to step therapy requirements. Your plan may require you to try older, less expensive diabetes medications like metformin or a sulfonylurea before they will approve a newer agent like Ozempic or Mounjaro. Your doctor will need to document why those preferred drugs are not appropriate for you.

References

  1. GoodRx Research. (2026). Insurance Coverage for GIP and GLP-1 Agonists. https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
  2. AJMC. (2025). Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss. https://www.ajmc.com/view/contributor-yearly-trends-in-coverage-rates-for-glp-1-ras-in-weight-loss
  3. CMS.gov. (2025). CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines. https://www.cms.gov/newsroom/press-releases/cms-launches-voluntary-model-expand-access-life-changing-medicines-promote-healthier-living
  4. Liu, X., et al. (2025). Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838260
  5. CMS.gov. (2026). CMS Interoperability and Prior Authorization Final Rule. https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f
  6. KFF. (2026). Recent Trends in GLP-1 Use and Spending in Medicare. https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/